All In Biotech

Drug Trial Radar · NCT03986138

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 324 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

324

Actual

Start

Aug 27, 2019

Primary completion

Dec 9, 2020

Study completion Dec 9, 2020

Sponsor

Lead sponsor
GuerbetIndustry
Sponsor type
Industry
First posted
Jun 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)

Conditions

  • Lesion in Body Region

Interventions

  • gadopiclenolDrug

    Single intravenous bolus injection

  • Gadobutrol 1 MMOLE/ML Intravenous SolutionDrug

    Single intravenous bolus injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRITime frame: At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.

Locations

33 sites in 11 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • UConn Health - University of Connecticut

    Farmington, Connecticut

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Boston Medical Center

    Boston, Massachusetts

  • University of Missouri Health System

    Columbia, Missouri

  • Montefiore Medical Center

    The Bronx, New York

  • UT Health San Antonio

    San Antonio, Texas

  • Acibadem City Clinic Tokuda Hospital Sofia

    Sofia, Bulgaria

  • CHU

    Angers, France

  • CHU Beaujon

    Clichy, France

  • Hôpital Saint Louis

    Paris, France

  • Klinik für Diagnostische und Interventionelle Radiologie

    Aachen, Germany

  • Universitätsklinikum Halle

    Halle, Germany

  • Universitätsklinikum des Saarlandes

    Homburg, Germany

  • University Hospital Jena

    Jena, Germany

  • Somogy Megyei Kaposi Mor Oktato Korhaz

    Kaposvár, Hungary

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, Hungary

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, Italy

  • Clinical Research Institute S.C.

    Estado de México, Mexico

  • Axis Heilsa S de R.L. de C.V - Althian Clinical Research Management Center

    Monterrey, Mexico

  • Szpital Uniwersytecki Nr 1 im. dr Antoniego Jurasza w Bydgoszczy

    Bydgoszcz, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Jagiellońskie Centrum Innowacji Sp. z o. o.

    Krakow, Poland

  • Szpital Świętego Rafała

    Krakow, Poland

  • Centrum Medyczne Affidea Wałbrzych

    Wałbrzych, Poland

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Bucheon Suncheonhyang Hospital

    Gyeonggi-do, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • St. Luke's Hospital

    Kropyvnytskyi, Ukraine

  • Borys Clinic

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.